Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ZKAB001 |
| Synonyms | |
| Therapy Description |
ZKAB001 is a monoclonal antibody targeting CD274 (PD-L1), which potentially induces antibody-dependent cell-mediated cytotoxicity (ADCC) and inhibition of tumor growth (PMID: 36469563). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ZKAB001 | ZKAB 001|ZKAB-001|Socazolimab|STIA1014|STI-A1014|STI A1014 | PD-L1/PD-1 antibody 132 | ZKAB001 is a monoclonal antibody targeting CD274 (PD-L1), which potentially induces antibody-dependent cell-mediated cytotoxicity (ADCC) and inhibition of tumor growth (PMID: 36469563). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|